Our Science
RdRp Thumb-1
Unlocking a Highly Conserved Vulnerability in Viral Biology
A Central Engine for Viral Replication
RdRp is essential for the replication and transcription of RNA viruses, acting as the engine that drives the synthesis of viral RNA. This enzyme is:
The Problem
Traditional antiviral approaches have focused on either nucleoside analog inhibitors, which mimic natural substrates to disrupt RdRp activity, or protease inhibitors, which block viral protein processing. However, these approaches are virus-specific, prone to resistance, and limited in scope. Targeting RdRp Thumb-1 offers a novel solution that transcends these limitations.
A Cryptic and Allosteric Vulnerability
Broad-Spectrum Potential
Unlike nucleoside analogs or protease inhibitors, which are virus-specific, targeting Thumb-1 disrupts the replication machinery common to all RNA viruses. This approach breaks away from the “one-virus, one-drug” paradigm, offering a universal solution for RNA virus infections.
The conserved nature of Thumb-1 significantly lowers the likelihood of resistance mutations, a critical limitation of existing antiviral therapies. The essential role of Thumb-1 in polymerase function ensures that structural alterations to evade drug binding would compromise viral fitness.
Allosteric targets like Thumb-1 provide a unique mechanism of action that complements existing antiviral strategies. By binding to a site distinct from the active site, Thumb-1 inhibitors avoid direct competition with natural substrates, enhancing both specificity and efficacy.
Targeting Thumb-1
Our research uncovered the Thumb-1 site through advanced structural biology techniques, including cryo-electron microscopy and computational modeling. Key insights include:
Disrupting the One-Virus, One-Drug Model
Traditional antiviral therapies have been reactive, addressing individual viral threats with tailored drugs. This approach is both resource-intensive and insufficient for pandemics involving novel or multiple viral strains. RdRp Thumb-1 inhibitors represent a shift toward proactive, universal therapeutics:
Global Health Impact
Broad-spectrum antivirals based on Thumb-1 inhibitors have the potential to protect billions of people worldwide.
They provide a scalable solution for resource-limited settings and enhance global pandemic preparedness.
Scientific Advancement
Redefines antiviral drug discovery by focusing on structural vulnerabilities shared across viral families.
Opens new avenues for the development of second-generation inhibitors and combination therapies.
Revolutionizing Antiviral Treatment
learn more
Partnerships
Join Us in Advancing Antiviral Innovation
Our pipeline is built on the foundation of bold science and transformative potential. We welcome partnerships to accelerate the development and deployment of these life-saving therapies.
Pipeline